Skip to main content
NIH funding notice RFA-AI-24-010

Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed)

Closed on June 28, 2024.

Posted
March 27, 2024
Close date
June 28, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,002,559 in first-year total cost, median $2,501,280.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 FDS-M (J1)]2

Most frequent institutions

  1. RUTGERS BIOMEDICAL AND HEALTH SCIENCES1
  2. UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
Competing awards under RFA-AI-24-010 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025FEND-TB1R01AI190528-01ALLAND, DAVIDDORMAN, SUSAN EELLNER, JERROLD J.RUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ$2,593,818ZAI1
2025Rapid Research for Diagnostics Development in TB Network: Episode 2 (R2D2 TB Network II)1R01AI190419-01CATTAMANCHI, ADITHYADENKINGER, CLAUDIA MARIANAHID, PAYAMUNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA$2,408,741ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.